[ad_1]
Rebecca’s Story
Rebecca, a 61-year-old grandmother and substitute teacher was diagnosed with a rare form of inflammatory breast cancer, underwent chemotherapy and a modified radical mastectomy. A month after her surgery, Rebecca developed multiple lesions below her mastectomy scar which turned out to be metastatic breast cancer to the skin.
Medical Moment of Truth
Rebecca and her doctors faced a choice of between the molecularly targeted therapies Piqray or Ibrance, either in combination with letrozole. Her tumor’s next-generation sequencing biomarker data revealed a PIK3CA H1047R mutation, which suggested that Piqray could be an effective treatment. But Rebecca’s medical records described a history of poorly controlled diabetes, and Piqray is known to cause or worsen high blood sugar in many patients who take it.
Personalized Treatments
Rebecca’s health plan was presented with a request for treatment with Piqray + letrozole at a 3-month cost of $54,828. Given that Piqray-based therapy has only been proven effective in the second-line setting, OncoHealth reviewed the data and found that a first-line treatment of Ibrance + letrozole could reduce the risk of death by 34%, avoid the risk of potentially life-threatening hyperglycemia, and result in a 3-month savings of $14,397.
24×7 Supportive Care
Rebecca became consumed with worry about the future. She started making excuses about attending social events and she began to feel isolated. Her health plan mentioned a new support service they were offering to all members undergoing cancer treatment called Iris. She signed up and began talking with a peer mentor who had also experienced breast cancer in midlife.
|
Sources 2/ https://oncohealth.us/ The mention sources can contact us to remove/changing this article |
[ad_2]